Australian-made disinfectant given a COVID-19-killing approved label claim

17 April 2020

Following recent changes to the Guidelines for Disinfectants under Therapeutic Goods Order 104, which allow listed disinfectants to make validated claims to kill the SARS-CoV-2 (COVID-19) virus on surfaces,  can confirm VIRACLEAN® , manufactured by the Whiteley Corporation, has the first newly approved label claim for killing the SARS-CoV-2 (COVID-19) virus on contaminated surfaces. 

Viraclean® is a hospital-grade disinfectant intended for use on a wide range of surfaces which may be contaminated, better protecting patients and staff from the risk of SARS-CoV-2 (COVID-19) virus cross infection. (It is important to note that the product is a surface disinfectant and not intended for use directly on people, or for treating a patient.) 

Given the capacity of COVID-19 to survive on hard and relatively soft surfaces for a prolonged period of time, cleaning and disinfecting those surfaces is incredibly important to limiting the spread of the virus. 

Speaking about the newly-added label claim Dr Greg Whiteley, Chairman of Whiteley Corporation, noted that “This new label claim for Viraclean® against the virus responsible for the current pandemic will add to certainty around the level of hygiene in hospitals, particularly in Intensive Care Units, Emergency Departments, and a range of other clinical, medical and dental applications. These claims will also be applied to INSTRUMAX® PINK, which is used for Disinfection of Non-Critical Medical Devices in the hospital and healthcare sector.” 

On a more technical comment Dr Whiteley said “The testing against Coronavirus in the case of this SARS-CoV-2 (COVID-19) relies on a number of surrogate viruses. This is important because using a surrogate protects the laboratory staff but allows a scientifically accurate representation of the disinfectant performance against all of the Coronaviruses including SARS-CoV-2 (COVID-19) virus. This approach allows the TGA to manage the regulatory aspects of both the approval and also market performance to ensure public health standards are maintained." 

For more information on dealing with COVID-19, go to the ADA's dedicated coronavirus site.